Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Dow
Mallinckrodt
Merck
AstraZeneca

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR LUMASON


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Lumason

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02282163 ↗ Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography Terminated Bracco Diagnostics, Inc Phase 3 2015-10-01 Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV EBD on non-contrast 2D echocardiography. Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.
NCT02522481 ↗ Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141 Completed Bracco Diagnostics, Inc Phase 3 2015-09-24 The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (CE-DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.
NCT02552238 ↗ Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142 Completed Bracco Diagnostics, Inc Phase 3 2015-10-12 The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.
NCT02911714 ↗ Contrast-Enhanced Ultrasound for Kidney Transplant Recruiting American Heart Association Phase 1 2018-02-21 Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in the early detection of kidney transplant complications, such as delayed graft function (DGF) and acute allograft rejection. The technique uses an intravenous contrast agent to improve organ visualization with standard duplex ultrasound equipment. A number of FDA-approved agents, including Optison, Definity and Lumason are widely used to improve visualization in technically limited echocardiograms, and Lumason was recently approved for contrast-enhanced ultrasound of the liver. The specific aims of this study are to: develop, implement and refine a contrast-enhanced ultrasound protocol using Lumason to safely maximize kidney allograft visualization; determine associations between contrast-enhanced ultrasound and patterns of allograft injury consistent with delayed graft function; and to compare contrast-enhanced ultrasound with duplex ultrasound for differentiating acute rejection from other causes of dysfunction.
NCT02911714 ↗ Contrast-Enhanced Ultrasound for Kidney Transplant Recruiting National Kidney Foundation Phase 1 2018-02-21 Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in the early detection of kidney transplant complications, such as delayed graft function (DGF) and acute allograft rejection. The technique uses an intravenous contrast agent to improve organ visualization with standard duplex ultrasound equipment. A number of FDA-approved agents, including Optison, Definity and Lumason are widely used to improve visualization in technically limited echocardiograms, and Lumason was recently approved for contrast-enhanced ultrasound of the liver. The specific aims of this study are to: develop, implement and refine a contrast-enhanced ultrasound protocol using Lumason to safely maximize kidney allograft visualization; determine associations between contrast-enhanced ultrasound and patterns of allograft injury consistent with delayed graft function; and to compare contrast-enhanced ultrasound with duplex ultrasound for differentiating acute rejection from other causes of dysfunction.
NCT02911714 ↗ Contrast-Enhanced Ultrasound for Kidney Transplant Recruiting Isaac E. Hall Phase 1 2018-02-21 Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in the early detection of kidney transplant complications, such as delayed graft function (DGF) and acute allograft rejection. The technique uses an intravenous contrast agent to improve organ visualization with standard duplex ultrasound equipment. A number of FDA-approved agents, including Optison, Definity and Lumason are widely used to improve visualization in technically limited echocardiograms, and Lumason was recently approved for contrast-enhanced ultrasound of the liver. The specific aims of this study are to: develop, implement and refine a contrast-enhanced ultrasound protocol using Lumason to safely maximize kidney allograft visualization; determine associations between contrast-enhanced ultrasound and patterns of allograft injury consistent with delayed graft function; and to compare contrast-enhanced ultrasound with duplex ultrasound for differentiating acute rejection from other causes of dysfunction.
NCT03040323 ↗ Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses Terminated Indiana University Phase 4 2016-12-22 The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lumason

Condition Name

Condition Name for Lumason
Intervention Trials
Hepatocellular Carcinoma 3
Coronary Artery Disease 2
Abdominal Injury 2
Kidney Transplantation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lumason
Intervention Trials
Abdominal Injuries 4
Carcinoma, Hepatocellular 3
Carcinoma 3
Wounds and Injuries 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lumason

Trials by Country

Trials by Country for Lumason
Location Trials
United States 47
Canada 2
United Kingdom 2
Germany 1
Belgium 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lumason
Location Trials
California 6
Missouri 5
Indiana 4
Massachusetts 4
Pennsylvania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lumason

Clinical Trial Phase

Clinical Trial Phase for Lumason
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 2 4
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lumason
Clinical Trial Phase Trials
Recruiting 10
Terminated 4
Completed 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lumason

Sponsor Name

Sponsor Name for Lumason
Sponsor Trials
Bracco Diagnostics, Inc 4
Mayo Clinic 3
Children's Hospital of Philadelphia 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lumason
Sponsor Trials
Other 30
Industry 6
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Mallinckrodt
Express Scripts
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.